Christopher Peetz Sells 20,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 20,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $122.27, for a total value of $2,445,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $23,758,161.43. The trade was a 9.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Peetz also recently made the following trade(s):

• On Monday, June 1st, Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM traded up $0.26 during trading hours on Wednesday, hitting $128.57. The company’s stock had a trading volume of 885,134 shares, compared to its average volume of 931,937. Mirum Pharmaceuticals, Inc. has a 12 month low of $50.25 and a 12 month high of $129.00. The company’s 50 day simple moving average is $104.54 and its two-hundred day simple moving average is $96.79. The company has a market cap of $7.84 billion, a P/E ratio of -9.45 and a beta of 0.48. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analysts’ expectations of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.Mirum Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.30) EPS. As a group, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on MIRM. TD Cowen raised their target price on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research note on Monday, June 15th. Finally, Evercore reaffirmed an “outperform” rating and issued a $138.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $143.40.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cullen Frost Bankers Inc. purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $30,000. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth $32,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 4th quarter worth $32,000. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals in the 3rd quarter worth $33,000. Finally, Summit Securities Group LLC bought a new position in Mirum Pharmaceuticals in the 1st quarter worth $42,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.